Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Ethylene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL7543163 | 1.00 | — | — | |
| Ethylene SCHEMBL9614894 | 0.95 | CA2 (0.47) | CA2CA5ACA5BKDM4ECYP3A4 | |
| Formaldehyde SCHEMBL21494159 | 0.90 | — | — | |
| SCHEMBL8596055 | 0.89 | CA2 (0.58) | CA2CA5ACA5BKDM4ECYP3A4 | |
| SCHEMBL25599 | 0.89 | CA2 (0.58) | CA2CA5ACA5BKDM4ECYP3A4 | |
| SCHEMBL246838 | 0.89 | CA2 (0.58) | CA2CA5ACA5BKDM4ECYP3A4 | |
| SCHEMBL128169 | 0.89 | — | — | |
| SCHEMBL105 | 0.89 | — | — | |
| SCHEMBL15109974 | 0.89 | — | — | |
| Formaldehyde SCHEMBL28129019 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117630382-A | Rat testis Leydig progenitor cell marker protein, screening method and application thereof | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 2024-03-01 | — | — | CN | disclosed |
| EP-3137081-B1 | BUPRENORPHINE DIMER AND ITS USE IN TREATMENT OF GASTROINTESTINAL DISORDERS | ORPHOMED INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9732096-B2 | Buprenorphine dimer and its use in treatment of gastrointestinal disorders | ORPHOMED, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2017074903-A1 | USE OF BUPRENORPHINE DIMER IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | ORPHOMED, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-3137081-A1 | BUPRENORPHINE DIMER AND ITS USE IN TREATMENT OF GASTROINTESTINAL DISORDERS | Orphomed, Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9549924-B2 | Use of buprenorphine dimer in the treatment of peripheral neuropathic pain | ORPHOMED, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160368932-A1 | BUPRENORPHINE DIMER AND ITS USE IN TREATMENT OF GASTROINTESTINAL DISORDERS | DIMERX, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9321780-B2 | Buprenorphine dimer and its use in treatment of gastrointestinal disorders | ORPHOMED, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160038481-A1 | USE OF BUPRENORPHINE DIMER IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | DIMERX, INC. | 2016-02-11 | — | — | US | disclosed |
| WO-2015168031-A1 | BUPRENORPHINE DIMER AND ITS USE IN TREATMENT OF GASTROINTESTINAL DISORDERS | OrphoMed LLC (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150307504-A1 | BUPRENORPHINE DIMER AND ITS USE IN TREATMENT OF GASTROINTESTINAL DISORDERS | DIMERX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-8507472-B2 | Bicyclic pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-0491872-B1 | POLYHALODIHYDRODIOXINS AND POLYHALODIOXOLES | DU PONT (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5334731-A | Using halogenated dioxoles prepared by the catalytic dechlorination of halogenated dioxolanes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
| US-5026801-A | Polyhalodihydrodioxins and polyhalodioxoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| WO-1991004251-A2 | POLYHALODIHYDRODIOXINS AND POLYHALODIOXOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368932-A1 | BUPRENORPHINE DIMER AND ITS USE IN TREATMENT OF GASTROINTESTINAL DISORDERS | OPRD1, OPRK1, OPRL1 | CA2 4558/4885CA5A 4581/4885CA5B 4500/4885 |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | PLPBP, PNPO, PIR | CA2 2784/4885CA5A 1379/4885CA5B 2003/4885 |
| US-20160038481-A1 | USE OF BUPRENORPHINE DIMER IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | OPRL1, OPRM1, OPRD1 | CA2 4783/4885CA5A 4791/4885CA5B 4543/4885 |
| US-20150307504-A1 | BUPRENORPHINE DIMER AND ITS USE IN TREATMENT OF GASTROINTESTINAL DISORDERS | OPRD1, OPRK1, OPRL1 | CA2 4558/4885CA5A 4581/4885CA5B 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.